Literature DB >> 8049141

The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines.

S P Langdon1, G L Hirst, E P Miller, R A Hawkins, A L Tesdale, J F Smyth, W R Miller.   

Abstract

The effects of 17 beta-estradiol (E2) on the growth and the levels of estrogen receptor (ER), progesterone receptor (PR) and pS2 protein were examined in a range of 8 ovarian carcinoma cell lines. E2 stimulated growth of the 3 cell lines with an ER content of 80-220 fmol/mg protein but not the 5 cell lines with ER concentrations less than 20 fmol/mg protein. After exposure to E2, ER concentration in 2 of the 3 responsive cell lines was decreased relative to untreated cells and in 2 lines, progesterone receptors were increased. No change in steroid receptor levels was observed in cell lines with low or negligible levels of receptors. The pS2 protein was not induced by E2 in the 5 ovarian carcinoma cell lines examined. These results indicate that E2 can stimulate the growth of some ER-positive ovarian carcinoma cells and that these effects may be associated with changes in the cellular levels of steroid hormone receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049141     DOI: 10.1016/0960-0760(94)90019-1

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  22 in total

1.  Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Authors:  Courtney L Andersen; Matthew J Sikora; Michelle M Boisen; Tianzhou Ma; Alec Christie; George Tseng; Yongseok Park; Soumya Luthra; Uma Chandran; Paul Haluska; Gina M Mantia-Smaldone; Kunle Odunsi; Karen McLean; Adrian V Lee; Esther Elishaev; Robert P Edwards; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

2.  MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Authors:  Karina E Hew; Philip C Miller; Dorraya El-Ashry; Jun Sun; Alexandra H Besser; Tan A Ince; Mengnan Gu; Zhi Wei; Gao Zhang; Patricia Brafford; Wei Gao; Yiling Lu; Gordon B Mills; Joyce M Slingerland; Fiona Simpkins
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

3.  Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Authors:  Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A Gilbert; Thiago da Silva; Ali Pedram; Ellis R Levin; Isildinha M Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A Ince; Ji-Yeon Yang; Roel G W Verhaak; Yiling Lu; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

4.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Authors:  David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

5.  Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status.

Authors:  C D Katsetos; I Stadnicka; J C Boyd; H Ehya; S Zheng; C M Soprano; H S Cooper; A S Patchefsky; D R Soprano; K J Soprano
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 6.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

7.  Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

8.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

Review 9.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

10.  Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells.

Authors:  G M Clinton; C Rougeot; J Derancourt; P Roger; A Defrenne; S Godyna; W S Argraves; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.